Similar articles

• Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis.

  Yamauchi PS, Lowe NJ. Yamauchi PS, et al. J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S135-8. doi: 10.1016/j.jaad.2005.11.1043. J Am Acad Dermatol. 2006. PMID: 16488328 No abstract available.
• Exacerbation of paranoid schizophrenia in a psoriatic patient after treatment with cyclosporine A, but not with etanercept.

  Di Nuzzo S, Zanni M, De Panfilis G. Di Nuzzo S, et al. J Drugs Dermatol. 2007 Oct;6(10):1046-7. J Drugs Dermatol. 2007. PMID: 17966184
• Refractory erythrodermic psoriasis in a child with an excellent outcome by using etanercept.

  Fraga NA, Paim Mde F, Follador I, Ramos AN, Rêgo VR. Fraga NA, et al. An Bras Dermatol. 2011 Jul-Aug;86(4 Suppl 1):S144-7. doi: 10.1590/s0365-05962011000700038. An Bras Dermatol. 2011. PMID: 22068796 English, Portuguese.
• Erythroderma in the era of biological therapies.

  Zattra E, Belloni Fortina A, Peserico A, Alaibac M. Zattra E, et al. Eur J Dermatol. 2012 Mar-Apr;22(2):167-71. doi: 10.1684/ejd.2011.1569. Eur J Dermatol. 2012. PMID: 22321651 Review.
• Etanercept for the treatment of psoriasis.

  Bissonnette R. Bissonnette R. Skin Therapy Lett. 2006 Feb;11(1):1-4. Skin Therapy Lett. 2006. PMID: 16485060 Review.